Indegene teams up with Microsoft to propel Generative AI adoption in Life Sciences

New Delhi: Indegene has forged a strategic alliance with Microsoft to empower global life sciences firms in embracing advanced Generative AI (GenAI) solutions. This collaboration aims to accelerate innovation across commercial, medical, regulatory, and clinical sectors.

Indegene and Microsoft are set to co-develop specialized medical and technology tools tailored for GenAI services and workflows. “GenAI presents a once-in-a-decade opportunity for life sciences companies to modernize business processes and reimagine the effectiveness and efficiency of their operations throughout the value chain,” remarked Tarun Mathur, Chief Technology Officer at Indegene. “Using GenAI, we’re closely working with many of our clients to solve specific business problems, with nearly 50 real-world use cases already in an advanced pilot stage.”

Alok Lall, Chief Operating Officer of Microsoft India & South Asia, emphasized, “According to a Microsoft-commissioned study conducted by IDC 1, a staggering 79% of healthcare organizations have now embraced AI. This demonstrates that the tangible business value of this transformation is indisputable. By seamlessly integrating Indegene’s domain knowledge with Microsoft Azure OpenAI Service and Microsoft Copilot, we stand at the forefront of advancing generative AI within the life sciences sector. This collaborative effort empowers life sciences companies to fully harness AI’s capabilities, fostering innovation and scalability within the industry.”

The partnership focuses on several strategic initiatives in its initial phase. Using Azure OpenAI Service, Indegene aims to streamline content creation and tagging processes across the life sciences ecosystem, enhancing content personalization and engagement with healthcare professionals (HCPs), patients, and stakeholders.

Furthermore, GenAI capabilities are set to revolutionize the medical content workflow, accelerating the sourcing and authoring of critical documents such as Clinical Study Reports (CSRs) and Protocols. These solutions from Indegene ensure compliance with stringent clinical and regulatory standards, facilitating faster innovation cycles and improved operational efficiency.

In the realm of clinical trials, Indegene’s integration of Microsoft Fabric will enhance data management capabilities, improving data ingestion, refinement, and reporting processes. This will enable more robust data analytics, ensure regulatory compliance, and enhance operational agility, thereby providing a competitive advantage in the dynamic life sciences marketplace.

Indegene, serving 20 of the world’s leading biopharma companies, aims to leverage its expertise to drive AI-powered transformations that enhance patient outcomes and operational excellence. “With a focus on the right use cases, a responsible and compliant approach to scaling up, and shared learnings, we put generative AI to work for our clients”, added Tarun.

The company’s ‘GenAI @ Work’ initiative, which includes training over 5,000 employees in GenAI applications and deploying Microsoft Copilot in core business processes, to enhance the automation and productivity of its employees underscores its commitment to preparing a future-ready workforce.